MHC

Major Histocompatibility Complex; MHC

MHC is a group of genes encoding proteins which are transferred to the cell surfaces to present the intracellular or extracellular, self or non-self antigens to the cells of the immune system, thereby helping T cells in differentiating self from non-self proteins, and initiating adaptive immune responses. MHC can be divided into 3 subtypes, MHC I, MHC II and MHC III, in which MHC I presents endogenous antigens (such as antigens produced by virus-infected cells or tumor cells) to activate cytotoxic T cells (CD8+ T cells); MHC II presents exogenous antigens (such as bacteria or parasites) to activate helper T cells (CD4+ T cells); MHC III does not directly participate in antigen presentation, but involves in immune regulation, inflammatory response and cell signaling. MHC is crucial for stem cell transplant (SCT), and could lead to graft-versus-host disease (GVHD)^[1]^[2].

References:

[1]. Deakin JE, et al., Evolution and comparative analysis of the MHC Class III inflammatory region. BMC Genomics. 2006 Nov 2;7:281. [Content Brief]

[2]. Sharma S K. Major Histocompatibility Complex[M]//Basics of Hematopoietic Stem Cell Transplant. Singapore: Springer Nature Singapore, 2023: 903-913.

MHC Isoform Specific Products:

MHC Isoform Comparison

MHC Related Products (112)
MHC Isoform Comparison

By Effects:	Inhibitors (36) Substrate (1) Ligands (8) Activators (6) Modulators (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P1745

InsB (9-23)		98.98%
InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes. InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes.

HY-P11303

PADRE peptide		98.11%
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4⁺ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8⁺ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.

HY-P1585A

Gp100 (25-33), human TFA		99.73%
Gp100 (25-33), human TFA (Hgp100 (25-33) (TFA)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human TFA is a 9-amino acid (AA) epitope restricted by MHC class I H-2D^b and recognized by the T cells. Gp100 (25-33), human TFA has immunogenicity and induces specific T cells. Gp100 (25-33), human TFA can be used for the cancer research, such as melanoma.

HY-P6312

ESAT6 Epitope	Ligand
ESAT6 Epitope is a ESAT6 CD4⁺ T cell epitope. ESAT6 Epitope binds to MHC class I molecules with an IC₅₀ value of approximately 180 nM. ESAT6 Epitope has weak immunogenicity. ESAT6 Epitope can be used in studies related to pulmonary tuberculosis.

HY-P11058

OVA(250-264)		98.14%
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8⁺ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.

HY-P990189

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)	Inhibitor
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma.

HY-P99135

Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3)	Inhibitor	99.16%
Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) is a mouse-derived IgG2b antibody inhibitor, targeting to mouse MHC Class I (H-2Kb). Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) reacts with the mouse H-2Kb, H-2Kk, H-2Kq, H-2Kr, H-2ks MHC class I alloantigens and not H-2Kd. Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) can block MHC Class I. Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) can be used for immunology research.

HY-P990187

Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114)		99%
Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse MHC Class II. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) does not react with I-Af, I-Ak, or I-As haplotypes. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) blocks MHC Class II and inhibit T cell generation. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) can be used for the researches of infection and immunology, such as influenza A virus (IAV) infection.

HY-P991257

MK-1966
MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatory T cells. MK-1966 can be used for the research of cancer , such as gastric cancer.

HY-P10581A

SIIVFEKL TFA		99.67%
SIIVFEKL TFA is a variant of the major MHC class I-restricted epitope SIINFEKL. SIIVFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cells. SIIVFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells.

HY-P5499

CMV pp65(13-27)	Ligand	98.05%
CMV pp65(13-27) is a biological active peptide. (This peptide is derived from amino acid residues 13 to 27 of the 65k lower matrix phosphoprotein of the human cytomegalovirus. It contains a nine-amino-acid sequence (LGPISGHVL) that matches the consensus binding motif for a major histocompatibility complex H2-Dd T-cell epitope.)

HY-152830

Adrixetinib	Activator	99.55%
Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with K_d values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma.

HY-P10582A

SIYNFEKL TFA		99.92%
SIYNFEKL TFA is a variant of major MHC class I-restricted epitope SIINFEKL. SIYNFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cell. SIYNFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells.

HY-P1899

Smcy HY Peptide (738-746)		98.21%
Smcy HY Peptide (738-746) is a H2-D^b-restricted peptide corresponding to amino acids 738-746 of Smcy protein.

HY-W168754

DB28	Inhibitor	99.92%
DB28 is a novel MR1 ligand. DB28 decreases cell surface expression of MR1 and competitively inhibits activation of MAIT cells by agonist ligands.

HY-P991750

Anti-pan MHC Class II (HLA II) Antibody (IVA12)	Inhibitor	99.27%
Anti-pan MHC Class II (HLA II) Antibody (IVA12) recognizes human HLA-II (HLA-DR, HLA-DP, and HLA-DQ). Anti-pan MHC Class II (HLA II) Antibody (IVA12) blocks MHC-II in vitro. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-157281

Photolumazine III		99.96%
Photolumazine III (PLIII) is a microbial metabolite and derivative of Riboflavin (HY-B0456). Photolumazine III binds MR1 with high specificity. Photolumazine III supports efficient TCR binding. Photolumazine III acts as an antigen to activate cells. Responses to Photolumazine III trigger immune reactions.

HY-P990188

Anti-Mouse MHC class II (I-A) Antibody (Y-3P)		98.852%
Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse MHC class II. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) reacts with mouse MHC Class II haplotypes I-Ab, I-Af, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, and weakly with I-Ak. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) blocks MHC class II and inhibits expansion of regulate T cells. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) can be used for the immunology research.

HY-152830A

Adrixetinib TFA	Activator	99.82%
Adrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with K_d values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma.

HY-P2525

GAD65 (206-220)		98.02%
GAD65 (206-220) is glutamic acid decarboxylase (GAD) 65-derived peptide, corresponding to residues 180-188. GAD65 is presented to T cells in association with I-Ag7 MHC class II molecules and a major pancreatic antigens targeted by self-reactive T cells in type I diabetes mellitus.

Name
Email *

	Sorry, but the email address you supplied was invalid.

MHC

MHC Isoform Specific Products:

MHC Isoform Specific Products:

MHC Related Products (112)

MHC Isoform Comparison

MHC Related Products (112):